Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Alimta
1.2.3 Iressa
1.2.4 Avastin
1.2.5 Tarceva
1.2.6 Zykadia
1.2.7 Tagrisso
1.2.8 Xalkori
1.2.9 Cyramza
1.2.10 Opdivo
1.2.11 Alecensa
1.3 Market by Application
1.3.1 Global Non-small Cell Lung Cancer Therapeutics Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-small Cell Lung Cancer Therapeutics Market Perspective (2018-2033)
2.2 Non-small Cell Lung Cancer Therapeutics Growth Trends by Region
2.2.1 Global Non-small Cell Lung Cancer Therapeutics Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Non-small Cell Lung Cancer Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2024-2033)
2.3 Non-small Cell Lung Cancer Therapeutics Market Dynamics
2.3.1 Non-small Cell Lung Cancer Therapeutics Industry Trends
2.3.2 Non-small Cell Lung Cancer Therapeutics Market Drivers
2.3.3 Non-small Cell Lung Cancer Therapeutics Market Challenges
2.3.4 Non-small Cell Lung Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue
3.1.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Non-small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-small Cell Lung Cancer Therapeutics Revenue
3.4 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Therapeutics Revenue in 2022
3.5 Non-small Cell Lung Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Non-small Cell Lung Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Non-small Cell Lung Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-small Cell Lung Cancer Therapeutics Breakdown Data by Type
4.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2024-2033)
5 Non-small Cell Lung Cancer Therapeutics Breakdown Data by Application
5.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Non-small Cell Lung Cancer Therapeutics Market Size (2018-2033)
6.2 North America Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2023)
6.4 North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-small Cell Lung Cancer Therapeutics Market Size (2018-2033)
7.2 Europe Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2023)
7.4 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size (2018-2033)
8.2 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-small Cell Lung Cancer Therapeutics Market Size (2018-2033)
9.2 Latin America Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size (2018-2033)
10.2 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Detail
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Introduction
11.1.4 GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
11.1.5 GlaxoSmithKline Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Introduction
11.2.4 Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Introduction
11.3.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
11.3.5 AstraZeneca Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Non-small Cell Lung Cancer Therapeutics Introduction
11.4.4 Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
11.4.5 Roche Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Detail
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Introduction
11.5.4 Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Introduction
11.6.4 Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Detail
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Introduction
11.7.4 Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
11.7.5 Eli Lilly Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Introduction
11.8.4 Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
11.8.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Alimta
Table 3. Key Players of Iressa
Table 4. Key Players of Avastin
Table 5. Key Players of Tarceva
Table 6. Key Players of Zykadia
Table 7. Key Players of Tagrisso
Table 8. Key Players of Xalkori
Table 9. Key Players of Cyramza
Table 10. Key Players of Opdivo
Table 11. Key Players of Alecensa
Table 12. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 13. Global Non-small Cell Lung Cancer Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 14. Global Non-small Cell Lung Cancer Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region (2018-2023)
Table 16. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 17. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region (2024-2033)
Table 18. Non-small Cell Lung Cancer Therapeutics Market Trends
Table 19. Non-small Cell Lung Cancer Therapeutics Market Drivers
Table 20. Non-small Cell Lung Cancer Therapeutics Market Challenges
Table 21. Non-small Cell Lung Cancer Therapeutics Market Restraints
Table 22. Global Non-small Cell Lung Cancer Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 23. Global Non-small Cell Lung Cancer Therapeutics Market Share by Players (2018-2023)
Table 24. Global Top Non-small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2022)
Table 25. Ranking of Global Top Non-small Cell Lung Cancer Therapeutics Companies by Revenue (US$ Million) in 2022
Table 26. Global 5 Largest Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Non-small Cell Lung Cancer Therapeutics Product Solution and Service
Table 29. Date of Enter into Non-small Cell Lung Cancer Therapeutics Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Non-small Cell Lung Cancer Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 32. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2018-2023)
Table 33. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 34. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2024-2033)
Table 35. Global Non-small Cell Lung Cancer Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 36. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2018-2023)
Table 37. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 38. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2024-2033)
Table 39. North America Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 40. North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 41. North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 42. Europe Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 45. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 46. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 47. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2024-2033) & (US$ Million)
Table 48. Latin America Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 49. Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 50. Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 51. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 52. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 53. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 54. GlaxoSmithKline Company Detail
Table 55. GlaxoSmithKline Business Overview
Table 56. GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Product
Table 57. GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 58. GlaxoSmithKline Recent Development
Table 59. Novartis Company Detail
Table 60. Novartis Business Overview
Table 61. Novartis Non-small Cell Lung Cancer Therapeutics Product
Table 62. Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 63. Novartis Recent Development
Table 64. AstraZeneca Company Detail
Table 65. AstraZeneca Business Overview
Table 66. AstraZeneca Non-small Cell Lung Cancer Therapeutics Product
Table 67. AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 68. AstraZeneca Recent Development
Table 69. Roche Company Detail
Table 70. Roche Business Overview
Table 71. Roche Non-small Cell Lung Cancer Therapeutics Product
Table 72. Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 73. Roche Recent Development
Table 74. Bristol-Myers Squibb Company Detail
Table 75. Bristol-Myers Squibb Business Overview
Table 76. Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Product
Table 77. Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 78. Bristol-Myers Squibb Recent Development
Table 79. Pfizer Company Detail
Table 80. Pfizer Business Overview
Table 81. Pfizer Non-small Cell Lung Cancer Therapeutics Product
Table 82. Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 83. Pfizer Recent Development
Table 84. Eli Lilly Company Detail
Table 85. Eli Lilly Business Overview
Table 86. Eli Lilly Non-small Cell Lung Cancer Therapeutics Product
Table 87. Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 88. Eli Lilly Recent Development
Table 89. Sanofi Company Detail
Table 90. Sanofi Business Overview
Table 91. Sanofi Non-small Cell Lung Cancer Therapeutics Product
Table 92. Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-small Cell Lung Cancer Therapeutics Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Non-small Cell Lung Cancer Therapeutics Market Share by Type: 2022 VS 2033
Figure 3. Alimta Features
Figure 4. Iressa Features
Figure 5. Avastin Features
Figure 6. Tarceva Features
Figure 7. Zykadia Features
Figure 8. Tagrisso Features
Figure 9. Xalkori Features
Figure 10. Cyramza Features
Figure 11. Opdivo Features
Figure 12. Alecensa Features
Figure 13. Global Non-small Cell Lung Cancer Therapeutics Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 14. Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2022 VS 2033
Figure 15. Hospital Case Studies
Figure 16. Clinic Case Studies
Figure 17. Non-small Cell Lung Cancer Therapeutics Report Years Considered
Figure 18. Global Non-small Cell Lung Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 19. Global Non-small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 20. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region: 2022 VS 2033
Figure 21. Global Non-small Cell Lung Cancer Therapeutics Market Share by Players in 2022
Figure 22. Global Top Non-small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2022)
Figure 23. The Top 10 and 5 Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue in 2022
Figure 24. North America Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. North America Non-small Cell Lung Cancer Therapeutics Market Share by Country (2018-2033)
Figure 26. United States Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Canada Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Europe Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Europe Non-small Cell Lung Cancer Therapeutics Market Share by Country (2018-2033)
Figure 30. Germany Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. France Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. U.K. Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Italy Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Russia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Nordic Countries Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Share by Region (2018-2033)
Figure 38. China Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Japan Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. South Korea Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. India Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Australia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Latin America Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Latin America Non-small Cell Lung Cancer Therapeutics Market Share by Country (2018-2033)
Figure 46. Mexico Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Brazil Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Share by Country (2018-2033)
Figure 50. Turkey Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 51. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 52. GlaxoSmithKline Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
Figure 53. Novartis Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
Figure 54. AstraZeneca Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
Figure 55. Roche Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
Figure 57. Pfizer Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
Figure 58. Eli Lilly Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
Figure 59. Sanofi Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed